Takeda recently unveiled data showing Entyvio was superior to AbbVie's Humira at achieving clinical remission in moderate-to-severe ulcerative colitis patients at 52 weeks.

These results could see Entyvio used more frequently and as an earlier line of therapy, a leading expert told FirstWord, though Johnson & Johnson and Merck & Co.'s Remicade is the most frequently prescribed anti-TNF for UC, rather than Humira.

To get a better understanding of how these results could change prescribing patterns, we are snap-polling US and EU3 (France, Germany and UK) based gastroenterologists with the following questions…

________

Q. Newly disclosed results from a Phase III study of patients with moderate-to-severe active ulcerative colitis show that Entyvio (vedolizumab) was superior to Humira (adalimumab) at achieving clinical remission at 52 weeks.

31.3 percent of patients given Entyvio achieved the primary endpoint of clinical remission, which was significantly more than 22.5 percent of those on Humira. Data also showed that 39.7 percent of patients in the Entyvio arm exhibited mucosal healing at week 52, versus 27.7 percent of those treated with Humira.

Patients enrolled in the study had previously had an inadequate response or intolerance to corticosteroids, immuno-modulators or a TNF-alpha antagonist other than Humira.

Do these results support first-line positioning of Entyvio in moderate-to-severe ulcerative colitis?

Yes

No

________

Q. In a real-world setting, how much impact do you expect these data to have on increasing the use of Entyvio as a first-line therapy for moderate-to-severe ulcerative colitis?

None

Slight impact

Moderate impact

Significant impact

Very significant impact

________

Q. Based on your real-world experience, what is your clinical assessment of Entyvio versus Remicade (infliximab) for the treatment of moderate-to-severe ulcerative colitis?

Entyvio is a superior therapy

Remicade is a superior therapy

They are comparable

________

Q. In which setting for the treatment of moderate-to-severe ulcerative colitis are you likely to use Entyvio most frequently in the future? 

Pre-TNF inhibitor therapy

Post-TNF inhibitor therapy

________

Q. Is Entyvio suited to a particular cohort of moderate-to-severe ulcerative colitis patients?

Broadly all moderate-to-severe patients

Patients with more moderate disease

Patients with more severe disease

________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.